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feature
PATENTS

Combination therapy patents: a new front
in evergreening
As pharmaceutical companies seek patent protection for combinations of cancer therapeutics, it is worthwhile to
assess what constitutes an ‘unexpected result’ for the purpose of an appropriate patent and whether randomized,
controlled trials of drug combinations have the ability to generate them.

T

he patent system is designed so that
inventors who bear the burden of
innovation risks and are successful
in their efforts have the potential to reap
substantial rewards. From a constitutional
perspective, however, the ultimate goal
is not the benefit of individual inventors
but the benefit to society as a whole1. The
government provides particular citizens
the right to exclude others from certain
products or activities for a limited time, in
the hope that doing so will lead to benefits
for everyone2.
Pharmaceutical companies have become
adept at legal and business strategies aimed
at extending the period of protection,
frequently through minor modifications
to a drug’s dosage, formulation or
delivery system3–5. Commonly known
as ‘evergreening’, these strategies allow
innovators to increase the period of
time during which their successful drug
can generate revenue against limited
competition, while imposing financial and
patient care costs on society3,4. Here, we
review the legal concepts of obviousness
and unexpected results — terms with
which both physicians and regulators
(for example, the US Food and Drug
Administration (FDA)) should be familiar
in light of the emergence of pharmaceutical
combination patents — and examine their
interaction with current clinical research.
In the highly profitable oncology sector,
we evaluated whether pharma companies
are employing a new variant of these
strategies by combining ‘backbone’ drugs
(widely accepted standards of care) with
other drugs likely to be used to treat a given
disease state3,4. Specifically, we focused our
efforts on a subset of combination therapies
developed in cancer as a case study. Using
publicly available information, we assess the
current patent and clinical trial landscapes
for this combination. We demonstrate
that this new front in evergreening not
only lacks the inventive nature typically
justifying the 20-year patent reward but
also leads to the design and development
of clinical trials that lack even the potential
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to yield unexpected results characteristic of
a patentable invention — a finding similar
to the strategic behaviors of drug- and
device-makers in generating and studying
drug–device combinations6. Given the
implications of these emerging strategic
behaviors, we close by offering a proposal
for clinical trial elements that are necessary
to provide a thoughtful evaluation of the
non-obviousness of combination therapy
patents, as well as suggesting ways in
which inter-agency collaboration at the
federal level could help both industry and
researchers focus on achieving optimal
innovation in the public interest.

A brief review of patentability

Five canonical elements are required of an
innovation for it to be patentable under
US law: the invention must be of proper
subject matter, useful, novel, non-obvious
and the application must include proper
disclosure7. Of particular relevance to
combination therapy patents, the inventor
must demonstrate that the invention would
not have been obvious to a person having
ordinary skill in the art (POSITA), which is
defined as a person who has the capability
to understand the scientific and engineering
principles applicable to the relevant art8,9.
Precise requirements vary according to the
case and the invention, but in most patent
cases involving drug development, the
POSITA has skills commensurate with an
advanced degree (for example, PhD or MD)
along with experience in the research or
treatment of the specific disease state(s)10. As
the US Supreme Court has noted, a POSITA
is expected to be a person of ordinary
creativity, one who is able to fit the teachings
of multiple patents together like pieces of
a puzzle8. Some recent courts have found
that a POSITA would also be supported by
the insights of a multi-disciplinary drug
discovery and development team10. If an
invention would be obvious to this creative
POSITA who is backed by a team, then the
court should reject the patent.
Importantly, the term ‘invention’
goes beyond the notion of tinkering.

A related concept, ‘obvious to try’, holds
that an invention is unpatentable when it is
comprised of a set of re-combined elements,
the various permutations of which would be
predictable to try8. Absolute predictability
is not required, nor does it matter whether
the trials of the re-combined elements
require extensive time, money and effort to
test11. Rather, the invention is unpatentable
if there is a finite number of identified
solutions — that is, a set of things to try
— and a POSITA would have a reasonable
expectation of success if he or she were
to try each of these solutions in turn8,11.
Multiple courts have explicitly stated that it
is normal for scientists to optimize each
of the variables in a known process to
improve on what is generally known already
— but that acts of optimization are not
themselves patentable11,12.
A claimant can potentially overcome
obviousness rejections by demonstrating
what are known as objective indicia of
an invention’s non-obviousness. These
may include achievement of commercial
success, fulfillment of a long felt but
unsolved need, prior unsuccessful attempts
by other POSITAs to solve the problem,
evidence that the field’s conventional
wisdom ‘teaches away’ from the inventor’s
solution, or unexpected results that a
POSITA would not anticipate8. Among
the objective indicia, generation of
unexpected results is the most common
avenue for successfully demonstrating
non-obviousness, particularly for
pharmaceutical inventions13,14. As courts
explain, the principle behind the doctrine
of unexpected results is straightforward:
an invention that exhibits a superior
characteristic or advantage in a way that
surprises even a skilled artisan immersed
in the field is clearly not obvious15.
Courts have determined that for a result
to be unexpected, it must differ from
the POSITA’s expected results in kind
rather than degree16. In the context of a
combination of two drugs that are each
effective when given sequentially, the
patent claimant must demonstrate that
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Box 1 | Key principles of oncology clinical trial design

Rather than hard and fast ‘laws’, the
following generally accepted precepts
in oncology clinical trials and oncology
clinical practice are known to both
practicing and researching oncologists
alike23. Consequently, these precepts help
to inform oncology’s prior art.
Precept 1: combination and
progression-free survival
Begin with two hypothetical drugs, A and
B, with different mechanisms of action,
each of which independently increases
the amount of time that a tumor does not
grow, or progression-free survival (PFS),
in a disease state. Combining A and B
would be expected to extend PFS (as well
as, possibly, the amount of time that the
patient lives, called overall survival (OS),
more than either of the individual drugs
alone.
If PFSA > 0 and PFSB > 0, and OSA > 0
and OSB > 0, then none of the following
are unexpected results:
PFSA+B > PFSA
PFSA+B > PFSB
OSA+B > OSA
OSA+B > OSB

Precept 2: sequential administration
and PFS
Sequentially administering individually
active chemotherapy agents is a standard
approach taken by practicing oncologists
in treating an incurable malignancy. The
goal is to extract maximal benefit from
a single drug before the tumor achieves
resistance to that drug. Administering
up front and in combination two drugs
that may otherwise be administered
sequentially may increase PFS without
impacting OS.
the properties of the combination are
specifically the result of having combined
the drugs, rather than reflecting properties
of one or both of the drugs, given alone
or sequentially. Consider, for example,
two modestly effective drugs that each
improves survival by two months when
given in sequence. Prolongation of survival
by, say, not two months but two years

If PFSA > 0 and PFSB > 0, then neither
of the following are unexpected results:
PFSA+B > PFSA→B
PFSA+B > PFSB→A

Precept 3: structurally similar drugs
behave similarly
When used in the same disease state, drugs
with the same mechanism of action are
likely to confer similar PFS and OS benefit.
If A ≅ C or B ≅ D, PFSA > 0 and PFSB >
0, and OSA > 0 and OSB > 0, then none of
the following are unexpected results:
PFSA+B > PFSC
PFSA+B > PFSD
OSA+B > OSC
OSA+B > OSD

Precept 4: the straw man
Many drugs, administered as single agents
with palliative intent in later lines of
therapy, appear to prolong PFS and OS by
clinically relevant amounts of time, but
only when compared to the counterfactuals
of administering a poorly performing drug
or no therapy at all. Combining two active
drugs with different mechanisms of action
will likely confer statistically and clinically
significant PFS and OS benefit when
compared to the third drug.
If PFSA > 0 and PFSB > 0, OSA > 0 and
OSB > 0, and both PFSE and OSE → 0, then
neither of the following are unexpected
results:
PFSA+B > PFSE
PFSA+B > OSE

and an observed decrease in side effects
by administering the two drugs as a
combination would be an unexpected result.

Combination therapy in medicine

The prior art. Combining two active
therapies into a single regimen is a common
practice in medicine: angiotensin-converting
enzyme inhibitors and diuretics in
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hypertension, long-acting beta agonists
and inhaled corticosteroids in chronic
obstructive pulmonary disease, and
combinations of antiretrovirals and
protease inhibitors in HIV are but three
widely prescribed examples. Oncology is
particularly fertile ground, as chemotherapy
combinations have been used to treat cancer
for well over a half-century, leading to the
cures of select malignancies in the 1960s and
1970s17–21. Consequently, combining two or
more drugs has become a standard approach
in the treatment of the vast majority of
cancers22. Testing whether patients who
receive the combination of therapies A and
B (A + B) have improved outcomes, relative
to those who receive either A or B alone,
became a standard approach in oncology
drug development23
With decades of accumulated experience,
key principles of oncology clinical trial
design have been derived and are distilled
in Box 1. These precepts are understood not
only by the sophisticated multi-disciplinary
drug discovery and development teams of the
modern age but, at the very least, are intuited
by clinical practitioners. Combining active
anticancer drugs in the search for more
efficacious regimens has been employed for
decades. Consequently, the resulting patent
claims may be entirely unpatentable, as the
combination approach has long existed in
the prior art and was obvious to try. In light
of these obviousness concerns, the question
becomes whether a clinical trial — in any
subspecialty of medicine — might produce
results so surprising that they would meet the
threshold of ‘unexpected’.
Discovering the unexpected. From the
clinical trial precepts in Box 1 flow features
necessary of a clinical trial of an oncology
combination therapy (A + B) to demonstrate
an unexpected result. First, clinical trial
participants ought to be randomly assigned
to either the intervention or the comparator
arm(s) — they must be randomized
controlled trials (RCTs). Randomization
helps ensure that the observed outcome of
the clinical trial is due to differences in the
treatments rather than biased treatment
arm assignment. Without randomization,
differences in outcomes can be driven by
baseline patient characteristics, rather than
differences in the treatments.
Second, the most appropriate comparator
arm(s) is a sequence (or sequences) of the
two drugs that make up the combination
(for example, A → B and/or B → A). If A +
B confers 12 months of survival while A → B
confers 6 months of survival, then combining
A and B is clearly advantageous. Alternatively,
if the comparator arm is, say, A followed by
something else, then claims about the benefit
1505
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Search results (54 combinations)
One of “pembrolizumab”, “nivolumab”, “atezolizumab”,
“durvalumab”, ”avelumab” or “cemiplimab”
and
One of “axitinib”, “cabozantinib”, “lenvatinib”,
“pazopanib”, “ponatinib”, “regorafenib”,
“sorafenib”, “sunitinib” or “vandetanib”
(n = 19,509 patents and patent applications)

Relevant patents and patent applications
Out of the 54 combinations searched for, relevant
patent activity was identified for 39 combinations*

Excluded patents and patent applications that:
• Were not specifically drafted for one or more
of the searched combinations
• Were not filed by the owner company of the
kinase inhibitor or monoclonal antibody in
question
• Required additional components beyond the
combination therapy, such as other antibodies
or proteins

Fig. 1 | Patent search strategy. TotalPatentOne (LexisNexis), a repository of patents and patent
applications, was searched for patents and patent applications covering the combinations of
VEGF-inhibiting small molecules and IO drugs listed. *Note: for each of the 15 combinations where initial
analysis did not yield any patents or patent applications meeting our criteria for inclusion, it remains
possible that, within the thousands of claims in these patents or others, there exist ones that could be
asserted for the purpose of evergreening the combination therapy.

act of combining cannot be made. Clinical
trials that allow crossover from comparator
to intervention arm at progression are unable
to make strong conclusions about overall
survival (OS — the amount of time between
randomization and the patient’s death)
without assuming that subsequent treatments
are similar in their effects on outcomes24.
Only utilization of pre-determined sequences
of therapy allow for meaningful comparison,
albeit with limitation of freedom of choice at
first progression.
Finally, the primary outcome measure of
the RCT ought to be OS. This is contrasted
with progression-free survival (PFS), a
surrogate outcome that measures the time
between randomization and the patient’s
disease getting worse (progressing) that has
controversially been relied on for recent
regulatory decisions25,26. As demonstrated
in Box 1, due to the nature of combining
individually active therapies, none of the
possible patentable PFS results would be
unexpected: given the individual activity
in the disease state of both A and B, the
POSITA would expect A + B to have equal
or greater PFS benefit to A → B or B → A,
and if A + B has lower PFS benefit, then the
point is moot.
Armed with a basic understanding of
patentability, oncology’s prior art, and
principles of clinical trials that ought to
be present to enable identification of truly
unexpected results, we can now turn our
attention to real-world applications. Let us
examine an emerging combination therapy
in oncology as a case example.

Evergreening combinations

The results of analyses in numerous clinical
trials suggesting the exceptional benefit
1506

of combining vascular endothelial growth
factor (VEGF) inhibitors with immune
checkpoint blockade (also referred to as
immunotherapy (IO)) were presented at the
European Society of Molecular Oncology
2020 Annual Meeting27–30. VEGF and IO
have individually demonstrated efficacy in a
variety of cancers, including advanced and
metastatic renal cell carcinoma (mRCC)31,32.
VEGF inhibitors reduce a tumor’s growth
by blocking its ability to recruit and build a
blood supply, while IO acts by inhibiting the
signals that a cancer uses to evade the body’s
immune system33. VEGF inhibitors may also
increase intratumoral T-cell infiltration, an
immunologic change that likely enhances
IO’s anticancer efficacy34.
Given the decades-long approach in
oncology of combining drugs with different
mechanisms of action, it would be obvious
for a POSITA to consider combining
these two therapies. In fact, VEGF–IO
combinations have been hypothesized
since 2006 (ref. 34), trialed in a variety
of cancers33, and have since become,
arguably, standard of care for the first-line
treatment of advanced or mRCC35. All of
this occurred before the 2020 trial result
announcements.
The VEGF–IO patent landscape. Given the
ongoing clinical investigation surrounding
VEGF–IO, it would be consistent with the
self-interested behavior of a corporation
to seek out patent protection for this
combination. We therefore set out to
determine whether substantial patent
activity — evidence beyond anecdote —
is occurring for combinations of drugs
ordinarily known by relevant oncology
practitioners. Given oncology’s prior

knowledge, these combinations are likely
to constitute obvious (or obvious to try)
formulations8. We searched TotalPatent
One (LexisNexis) during July and August
2020 for 54 combinations of drugs,
containing one each of FDA-approved
VEGF or multi-tyrosine kinase inhibitors
— axitinib, cabozantinib, lenvatinib,
pazopanib, ponatinib, regorafenib,
sorafenib, sunitinib, and vandetanib —
and FDA-approved programmed cell
death protein 1 (PD-1)-axis-inhibiting IO
monoclonal antibodies — pembrolizumab,
nivolumab, atezolizumab, durvalumab,
avelumab and cemiplimab.
Our database search yielded 19,509
patents and patent applications (Fig. 1).
Among these, we considered only patents
filed by the owner company of the VEGF
drug or IO monoclonal antibody in
question, given that such patents are the
most likely to suggest that a company is
attempting to evergreen the protections
on an existing drug therapy3. To verify
that at least some of the claims within the
patents were specifically drafted to the drug
combination in question, and to eliminate
any patents that specified additional
components beyond the combination
therapy, such as other antibodies or
proteins, we examined in detail those
patents determined to be the most relevant
for a given drug combination. Selection of
the most relevant patent is best illustrated
with an example: if two similar patent
applications were identified for the same
drug combination, one mentioning the
drug combination in the specifications
and the other mentioning it in both the
specifications and the claims, we evaluated
the latter. Once an example of patent activity
meeting these criteria for one of the 54 drug
combinations was identified, we proceeded
to the subsequent drug combination.
In this manner, we identified patent
activity pertaining to 39 of the 54 drug
combinations searched, presented in
Supplementary Table 1. The results
demonstrate that, across a variety of specific
formulations, those companies likely to have
incentive to engage in evergreening behavior
have been, and continue to be, engaged
in substantial patent activity for drug
combinations known to those in the field.
Given the discussion above and the potential
implications of evergreening, this area of
patenting and drug development merited
critical evaluation.
Teaching away. A patent claimant
can overcome obviousness concerns
by demonstrating objective indicia of
non-obviousness, such as when the prior
art teaches away from an invention. That is,
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Search results (54 combinations)
One of “pembrolizumab”, “nivolumab”, “atezolizumab”,
“durvalumab”, ”avelumab” or “cemiplimab”
and
One of “axitinib”, “cabozantinib”, “lenvatinib”,
“pazopanib”, “ponatinib”, “regorafenib”,
“sorafenib”, “sunitinib” or “vandetanib”
(n = 187 clinical trials)
58 duplicate entries, registry or basket trials removed
Clinical trials eligible for review
(n = 129)

Clinical trials
(n = 24)
IO–TKI combinations
Lenvatinib–Pembrolizumab, n = 12
Cabozantinib–Nivolumab, n = 5
Cabozantinib–Atezolizumab, n = 4
Axitinib–Pembrolizumab, n = 1
Axitinib–Nivolumab, n = 1
Axitinib–Avelumab, n = 1

79 non-randomized trials
21 not assessing a contemporaneous combination
of IO–TKI therapy
2 not assessing overall survival or recurrence-free
survival
3 withdrawn or suspended trials

Study phase
Not applicable, n = 1
Phase 2, n = 3
Phase 3, n = 2

Fig. 2 | Identification of clinical trials evaluating the combination of VEGF inhibitors and IO agents
from ClinicalTrials.gov. Starting with search results of 187 clinical trials, 129 distinct clinical trials were
identified. Out of these, 105 trials were excluded from further analysis for non-randomized design,
failure to utilize contemporaneous combination or withdrawal/suspension of the study. The remaining
24 RCTs were included in the final analysis. TKI, tyrosine kinase inhibitor; IO, immunotherapy.

was there evidence in the prior art telling
inventors not to combine VEGF and IO?
Early phase 1 clinical trial work conducted
between 2012 and 2014 and publicly
disclosed in 2014 evaluated two VEGF–IO
combinations in mRCC. In these clinical
trials, sunitinib–nivolumab and pazopanib–
nivolumab demonstrated approximately
70% and 60%, respectively, grade 3/4 adverse
event rates36,37. A subsequent phase 1/2 study
of pazopanib–pembrolizumab in mRCC
conducted between 2013 and 2017 and
publicly disclosed in 2017 demonstrated
grade 3/4 adverse events of >80% and at
the time concluded that certain VEGF–IO
combinations were unsuitable for RCTs38,39.
At first glance, these studies — having raised
the possibility of a VEGF–IO combination
conferring prohibitive toxicity — may have
taught away from VEGF–IO combination
therapy. To the POSITA with experience in
drug discovery and development, though,
the observed toxicities were ‘off-target’
effects of the particular VEGF drugs tested
that would not be expected to generalize
to all VEGF inhibitors, as demonstrated by
the first-in-class axitinib–pembrolizumab
combination40.
VEGF–IO clinical trials. As the most
commonly used objective indicium for
overcoming obviousness concerns is

demonstration of an unexpected result, we
asked whether the RCTs in the VEGF–IO
development space have the capacity to
demonstrate an unexpected result, if one
were to exist. To examine this landscape,
we searched the National Clinical Trials
Registry (ClinicalTrials.gov) on 20 August
2020 for each of the 54 combinations of one
of the above VEGF inhibitors and one of the
above IO drugs. Building on two of the key
clinical trial principles described above —
(1) randomization; and (2) evaluation of OS
as a primary or co-primary endpoint — we
excluded any clinical trials that were not
randomized; did not contemporaneously
administer one of the above combinations;
assessed a primary endpoint(s) other than
OS, PFS or recurrence-free survival; or
indexed in ClinicalTrials.gov as having a
status other than ‘active, not recruiting’ or
‘completed’ (Fig. 2).
We identified 24 eligible RCTs,
summarized in Supplementary Table 2,
with total anticipated enrollment of 14,614
patient volunteers. Twelve (50%) trials
evaluate lenvatinib–pembrolizumab and
cabozantinib–nivolumab and cabozantinib–
atezolizumab are each evaluated by four
(17%). Twenty-one (88%) are phase 3
trials, and the remaining three (13%) are
randomized phase 2 trials. Nineteen (79%)
are industry-funded trials and five (21%) are
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government-funded. These trials used five
dominant designs:
Type 1: A + B versus A;
Type 2: A + B versus B;
Type 3: A + B versus C;
Type 4: A + B versus D;
Type 5: A + B versus E;
in which A is one of the VEGF inhibitors
listed above, B is one of the IO agents listed
above, C is an established and related VEGF
inhibitor (for example, sunitinib), D is an
established but unrelated standard of care
(for example, chemotherapy, physician’s
choice) and E is a non-active comparator
(placebo or otherwise).
Importantly, none of the 24 eligible
RCTs possess the three criteria needed to
demonstrate an unexpected result that were
derived above: randomization, sequential
treatment with A and B as a comparator, and
OS as the primary or co-primary endpoint.
The absence of sequential treatments is clear.
Thirteen of the 24 eligible RCTs employ
comparator arms that include at least one
drug from the VEGF–IO combination.
None incorporate A → B or B → A as a
comparator, and there is no pre-specified OS
or PFS analysis of A + B compared to A →
B or B → A subpopulations. Consequently,
these RCTs cannot demonstrate an
unexpected result attributable to the act
of combining6. Nine of the 13 trials that
include either A or B as a component of the
comparator arm employ OS as the primary
or co-primary endpoint (Supplementary
Table 2). Representative RCTs are discussed
in Box 2.
Importantly, five (21%) type-3 trials
were identified. Four of these trials were
conducted in mRCC and compared
VEGF–IO combinations to sunitinib;
all have reported results. First, axitinib–
avelumab, in the JAVELIN Renal-101
study reported on 21 March 2019, failed to
demonstrate benefit of the combination41.
Second, axitinib–pembrolizumab, in the
KEYNOTE-426 study also reported on 21
March 2019, demonstrated an OS benefit35.
The remaining two RCTs, evaluating
cabozantinib–nivolumab and lenvatinib–
pembrolizumab, continued to randomize
patients to sunitinib control arms after the
announcement of KEYNOTE-426 results42,43.
Nearly 24 months after KEYNOTE-426
publication, in March 2021, the CheckMate
9ER trial of cabozantinib–nivolumab was
published, demonstrating modest PFS and
OS benefits44; FDA approval had occurred
6 weeks earlier45. One month later, in April
2021, the CLEAR trial evaluating lenvatinib–
pembrolizumab in mRCC failed to
demonstrate any more than a modest benefit
in OS46, yet FDA approval followed 4 months
later47. Complicating interpretation of the
1507
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Box 2 | Representative randomized controlled trials

The most common combination
Twelve of the eligible RCTs evaluate the
lenvatinib–pembrolizumab combination,
but as presently designed none have the
design features needed to demonstrate
an unexpected result51–62. Seven of
the lenvatinib–pembrolizumab RCTs
incorporate pembrolizumab or lenvatinib
monotherapy as a comparator arm51–57.
Only two of the lenvatinib–pembrolizumab
RCTs fail to utilize OS as a co-primary
endpoint58,59. Critically, none of the
lenvatinib–pembrolizumab trials require
crossover to lenvatinib (in the case of
pembrolizumab) or pembrolizumab (in the
case of lenvatinib) at the time of disease
progression.
None of the trials utilize OS as the sole
primary endpoint. After having learned
that the FDA will award approvals to
VEGF–IO combination therapies on
the basis of PFS benefit63, trial sponsors
lack the incentive to wait for an OS
endpoint to read out before seeking
regulatory approval. All but one of the
clinical trials involving the combination
of lenvatinib and pembrolizumab are
industry-sponsored and expect to enroll
7,038 patients; the one trial sponsored by a
public entity will enroll 192 patients59.
How trials can be skewed
The LEAP-008 RCT evaluates lenvatinib–
pembrolizumab against docetaxel or
lenvatinib monotherapy as second-line
treatment for metastatic non-small cell
lung cancer that had progressed despite
prior PD-1-axis-inhibiting therapy. It
serves as an example for the myriad
ways in which clinical trial design can
be ‘gamed’ to achieve a desired outcome.
First, despite the publication of evidence
demonstrating modest OS benefit with the
addition of ramucirumab to docetaxel four
years before its opening64, LEAP-008 fails

mRCC VEGF–IO trials still further, nearly
all enrolled a substantial number of patients
from countries where access to IO only
occurs through clinical trials, increasing
the likelihood that patients randomized to
the sunitinib arms of these studies would
never receive standard-of-care, second-line
IO in the event of disease progression, and
thereby overestimating the OS benefit of
VEGF–IO48.

Recommendations

Reviewing the available evidence, the RCTs
of VEGF–IO combinations appear designed
1508

to incorporate VEGF-inhibiting therapy
in the comparator arm. Second, although
lenvatinib is one of the comparator arms of
the study, no crossover to pembrolizumab
monotherapy after progression on
lenvatinib is mandated. Third, given the
long half-life and target engagement
of IO65, it is possible that lenvatinib
administered in short succession following
progression through pembrolizumab may
‘rescue’ durable IO response. LEAP-008,
however, incorporates a 4-week washout
period, reducing the probability of
observing this phenomenon in a sequential
administration paradigm. Fourth, LEAP008 employs an unusual randomization
schema of 4:4:1 to lenvatinib–
pembrolizumab to docetaxel to lenvatinib.
Despite stratification on whether IO was
a remote therapy or the immediate prior
therapy, LEAP-008’s ability to disentangle
lenvatinib’s relative contribution to the
efficacy of lenvatinib–pembrolizumab
is likely to be limited due to only 45
patients receiving lenvatinib monotherapy.
Due to these issues, LEAP-008 cannot
demonstrate an unexpected result.
How do government-funded RCTs do?
Lest we think these design flaws only
occur in industry-sponsored clinical
trials, NCT03595124 is a National Cancer
Institute-funded RCT opened in July
2018 comparing axitinib–nivolumab
(A + B) to axitinib (A) and nivolumab
(B) monotherapy arms in transcription
factor E family translocation-positive
RCC66. Crossover in the comparator arms
at the time of progression from axitinib
to nivolumab (A → B) or nivolumab to
axitinib (B → A) is not pre-specified,
however, and the study’s primary endpoint
is PFS. Despite reasonable first choices for
comparator arms, NCT03595124 cannot
demonstrate an unexpected result.

to achieve FDA approval, rather than
identify truly unexpected or scientifically
novel results that would overcome
obviousness concerns. While such approvals
will yield significant financial rewards for
the drug sponsor(s), they should not result
in extension of exclusivity in the absence of a
demonstration of non-obviousness through
the discovery of unexpected results.
In truth, encouraging combination
patents and RCTs that do not aim to identify
unexpected results carries societal costs.
First, the limited resources that can be
dedicated to research and development

efforts are directed away from the truly
innovative approaches that represent the
constitutional goal of the patent system
and toward the commercialization of
combinations that are, in the context
of oncology’s prior art, non-innovative.
Second, even if VEGF–IO patents were
to be invalidated in court, the time and
expense required to challenge them
often deters competitors from entering
the market, interfering with the natural
competitive forces expected to discipline
high prices4. In short, this new frontier in
evergreening raises serious societal concerns
and requires coordinated action from all
involved parties — from the end users who
have demand for these products and the
government-supported entities that enable
patent-seeking research rather than true
innovation, through to the executive branch
entities responsible for conferring patents.
Physicians, as end users of combination
therapies, bear a societal responsibility to
be thoughtful producers and consumers of
biomedical research — industry-sponsored
or not. As with any therapy, physicians
should reflect on the designs of the relevant
combination therapy clinical trials. In
the context of cancer, oncologists need to
disabuse themselves of the notion that ‘more
therapy is better and in the best interests of
the patient’. Learning health systems would
be wise to assess the real-world outcomes
of patients treated with combination
therapies, especially as the gap between
performance as observed in clinical trials
versus real life yawns. Finally, disclosure of
the shortcomings of clinical trial design is
an absolutely necessary component in the
desired goal of clinical care — shared clinical
decision-making.
Clinical trialists and institutions have
critical roles in the current pharmaceutical
research and development landscape; it
is this infrastructure that enables both
innovative and non-innovative research.
Realizing that the potential benefits of
a clinical trial redound to patients other
than the ones for which they care, clinical
trialists must ask themselves, “Is the trial
on which I am proposing to enroll patients
something new or is it an incremental step?”
It is unlikely physicians can do this alone,
but demanding more from the research
that we and others design and enact is
a good first step, along with thoughtful
skepticism toward certain types of patent
claims. Similarly, the academic research
infrastructure, as well as the cachet, on
which many non-innovative clinical trials
rest is supported in no small part by federal
grants. Within the context of oncology,
the National Cancer Institute designated
53 Comprehensive Cancer Centers in the
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United States, with federal grant support
(P30) exceeding US$265 million in fiscal
year 2020 (ref. 49). Incorporating review of
the relative amounts of industry- versus
non-industry-sponsored research activity
occurring at a given cancer center in the
NCI P30 grant renewal process may help
to promote truly innovative research.
The concept of taxpayers ‘paying twice’
for drug development — once through
government-funded research and again in
the form of high drug prices — has gained
traction during the COVID-19 pandemic
and should be seriously considered.
As the guardian of the patent and
drug-making processes, coordinated federal
action on the part of the US Patent and
Trademark Office (USPTO) and FDA is
important. As the prior arts of medicine’s
subspecialties become increasingly complex,
the case for inter-agency collaboration
between the USPTO and FDA becomes
stronger. The FDA has the capacity to
provide information about all registered
clinical trials, fully informing the prior art
and context that the USPTO requires to
make its determinations. The FDA also has a
supply of experts who can provide additional
perspective for USPTO examiners, who
are rarely (if ever) clinicians (for example,
physicians, pharmacists) or pharmaceutical
scientists — FDA experts would be, to a first
approximation, the government’s best proxy
for a well-informed POSITA. In addition,
the USPTO is optimally positioned to
communicate to researchers and industry
the requirements for patentability and
to issue guidance on what constitutes
unexpected results (positive or negative) in
clinical trials.
The challenge in designing interagency
cooperation is to ensure that the process
is meaningful, rather than pro forma
or simply burdensome. Fortunately, the
USPTO has a model in place to better
inform prior art determinations. In 2019,
USPTO director Andrei Iancu reported
to the Senate Judiciary Subcommittee on
Intellectual Property that the USPTO was
piloting projects to help examiners better
identify prior art by collaboration between
multiple USTPO examiners, as well as
examiners from foreign patent offices50.
This project could be expanded to include
expertise closer to home — specifically at
the FDA. Such guidance for the USPTO
is in the interests of both drug developers
(by providing a measure of certainty) and
the public (by enhancing the risk–benefit
calculus of biomedical research). Similarly,
any regulatory standards that emerge at
the USPTO could be incorporated by the
FDA into its oversight of clinical trials and
more fully inform its safety and efficacy

determinations. This would allow both
agencies to better carry out their mandates
in serving the public interest.
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